Leukemia, Lymphocytic, Chronic, B-Cell: all 1,648 studies
Page 9 of 17. Open to participants first (245), then studies with results posted, then the rest; newest registration first within each.
- Mobilising Tumour and Immune Cells Via Exercise in Chronic Lymphocytic LeukaemiaCompletedNCT05093192Not applicable
- Belimumab in Patients with Chronic Lymphocytic LeukemiaActive, not recruitingNCT05069051Phase 2
- A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT05057494Phase 3
- Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.Status unknownNCT05049473Phase 2
- Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and LymphomaWithdrawnNCT05037669Phase 1
- Study of Oral LOXO-338 in Patients With Advanced Blood CancersCompletedNCT05024045Phase 1
- NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell CancersActive, not recruitingNCT05020678Phase 1
- Vaccine Responsiveness in Patients With Chronic Lymphocytic LeukemiaCompletedNCT05007860
- PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell MalignanciesStatus unknownNCT05003141Phase 1
- CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHLWithdrawnNCT04995536Phase 1
- A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter SyndromeTerminatedNCT04978779Phase 1
- A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Active, not recruitingNCT04965493Phase 3
- Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic LeukemiaCompletedNCT04964908
- B-cell Chronic Lymphoid Malignancies MarkersStatus unknownNCT04952974
- Exercise Training to Promote Resilience to Chronic Lymphocytic LeukemiaCompletedNCT04950452Not applicable
- MEOI and HRQoL in CLL Patients Treated With BTKisCompletedNCT04938141
- HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation CyclophosphamideActive, not recruitingNCT04904588Phase 2
- Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AMLTerminatedNCT04887259Phase 1
- Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLLCompletedNCT04883749Phase 2
- A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLLCompletedNCT04876092Phase 1
- Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient InvestigationCompletedNCT04872621
- Safety, Efficacy of BNT162b2 mRNA Vaccine in CLLStatus unknownNCT04862806Not applicable
- Immune Responses to COVID-19 Vaccination in Lymphoma PatientsCompletedNCT04858568
- Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT04852822
- Safe Accelerated Venetoclax Escalation in CLLActive, not recruitingNCT04843904Phase 1
- Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies MalignanciesStatus unknownNCT04823091Phase 1
- Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell TumorsStatus unknownNCT04814004Phase 1
- Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic LeukemiaTerminatedNCT04806035Phase 1
- Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological MalignanciesStatus unknownNCT04796688Phase 1
- Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid MalignanciesStatus unknownNCT04796675Phase 1
- Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter TransformationWithdrawnNCT04781855Phase 1
- Effect of Digital Health Coaching Program on Self-efficacy and Patient Reported Outcomes of Patients With Newly Diagnosed Acute Myeloid Leukemia or Chronic Lymphocytic LeukemiaCompletedNCT04774744Not applicable
- Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic MalignanciesStatus unknownNCT04767308Early Phase 1
- First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ MalignanciesStatus unknownNCT04763083Phase 1
- Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From CerdulatinibNo longer availableNCT04757259
- Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic LeukemiaActive, not recruitingNCT04754035Phase 2
- Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic MalignanciesCompletedNCT04748185
- Induced-T Cell Like NK Cells for B Cell MalignanciesStatus unknownNCT04747093Phase 1/2
- ALICIA (Acalabrutinib in CLL Therapy)CompletedNCT04746950
- Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid MalignanciesActive, not recruitingNCT04732845Phase 1
- A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLLActive, not recruitingNCT04722172Phase 2
- Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)CompletedNCT04716075Phase 2
- A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaWithdrawnNCT04694560
- Anakinra in Previously Untreated Chronic Lymphocytic Leukemia PatientsStatus unknownNCT04691765Phase 1
- Personalized Multi-peptide Vaccination in CLL PatientsCompletedNCT04688385Phase 1
- Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLLWithdrawnNCT04685915Phase 2
- huCART19-IL18 in CD19+ CancersActive, not recruitingNCT04684563Phase 1
- A Study of FCN-338 in Patients With Chronic CLL/SLLActive, not recruitingNCT04682808Phase 1
- Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's TransformationActive, not recruitingNCT04679012Phase 2
- SARS-CoV-2 Donor-Recipient Immunity TransferCompletedNCT04666025
- Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)WithdrawnNCT04665115Phase 2
- Early Intervention With Acalabrutinib in Patients With High Risk CLLWithdrawnNCT04660045Phase 2
- A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaCompletedNCT04657224Phase 1
- Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection to Assess Achievement of Best Response in Adult Participants With Chronic Lymphocytic LeukemiaTerminatedNCT04655261
- CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and LymphomaStatus unknownNCT04649983Phase 1/2
- Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and LymphomaStatus unknownNCT04648475Phase 1/2
- Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL PatientsStatus unknownNCT04640909Not applicable
- FT819 in Subjects With B-cell MalignanciesActive, not recruitingNCT04629729Phase 1
- Intermittent Fasting and CLL/SLLCompletedNCT04626843Phase 1
- Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's SyndromeActive, not recruitingNCT04623541Phase 1/2
- CD19-CAR-T2 Cells for CD19 Positive B Cell MalignanciesCompletedNCT04605666Phase 2
- Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer MedicationsTerminatedNCT04595851Not applicable
- CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell LymphomaCompletedNCT04578600Phase 1
- Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLLActive, not recruitingNCT04560322Phase 2
- Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed CancersTerminatedNCT04553692Phase 1
- The clonoSEQ® Watch RegistryTerminatedNCT04545333
- Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)Active, not recruitingNCT04542824Phase 1/2
- A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)CompletedNCT04540796Phase 1
- Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCTStatus unknownNCT04516551Phase 1
- Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid LeukemiaCompletedNCT04512105Phase 1
- Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic LeukemiaActive, not recruitingNCT04505254Phase 2
- Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic MalignanciesTerminatedNCT04504708Phase 1/2
- Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLLStatus unknownNCT04502394Phase 1/2
- Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)CompletedNCT04502030Phase 3
- Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on VenetoclaxActive, not recruitingNCT04501939Phase 2
- Long-term Follow-up Study for Patients Treated With CLBR001 CAR-TCompletedNCT04488354Phase 1
- 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell CancersActive, not recruitingNCT04464200Phase 1
- Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT04458610Phase 2
- CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell MalignanciesCompletedNCT04450069Phase 1
- The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)Active, not recruitingNCT04447768Phase 2
- A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT04434196Phase 1
- Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With VenetoclaxActive, not recruitingNCT04419519Phase 2
- Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)Active, not recruitingNCT04416984Phase 1/2
- Atrial Fibrillation in Patients Receiving IbrutinibStatus unknownNCT04407845
- Observatory of Patients With Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenstrom Disease Infected With COVID-19CompletedNCT04391946
- MyPal ePRO-based Early Palliative Care System in Adult Patients With Hematologic MalignanciesStatus unknownNCT04370457Not applicable
- A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell LymphomaStatus unknownNCT04356846Phase 1
- Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FLTerminatedNCT04342117
- Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's LymphomasTerminatedNCT04305444Phase 2
- Determination of Blood Tumor CellsCompletedNCT04290923
- Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in ItalyActive, not recruitingNCT04282811
- DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic CancerCompletedNCT04282343Not applicable
- CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic MalignanciesWithdrawnNCT04282174Phase 2
- A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic MalignanciesCompletedNCT04279405Phase 1
- Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and LymphomaStatus unknownNCT04271800Phase 1/2
- CD19/CD20 Dual-CAR-T in B-cell Leukemia PatientsCompletedNCT04260945Phase 1
- FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal AntibodiesTerminatedNCT04245722Phase 1
- Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHLTerminatedNCT04240704Phase 1
- Dietary Intervention With High Phenolic EVOO in CLLCompletedNCT04215367Not applicable
- A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaCompletedNCT04210219Phase 1